Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Techsin Ty

Internal Medicine Kokomo, IN Medical Doctor

NPI 1992705156 CMS profile 363068

3608 S Lafountain St Unit A, Kokomo, IN 46902

Open in the dashboard

General payments

$11,092

625 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Techsin Ty of Kokomo, IN is reported in the CMS Open Payments database as having received $11,092 across 625 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,057 139
2024 General $1,525 105
2023 General $1,821 111
2022 General $3,272 102
2020 General $378 25
2019 General $2,038 143

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Techsin Ty
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Techsin Ty were reported at $2,057. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Techsin Ty Internal Medicine median Middle half National median
2019 $2,038 $159 $48–$570 $163
2020 $378 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $3,272 $141 $42–$496 $149
2023 $1,821 $149 $45–$519 $160
2024 $1,525 $154 $47–$537 $164
2025 $2,057 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,776 88 payments
  2. AstraZeneca Pharmaceuticals LP $1,683 86 payments
  3. Novo Nordisk Inc $1,226 103 payments
  4. Amgen Inc. $542 27 payments
  5. Pfizer Inc. $533 33 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $526 37 payments
  7. Otsuka America Pharmaceutical, Inc. $388 29 payments
  8. Lilly USA, LLC $384 23 payments
  9. Novartis Pharmaceuticals Corporation $283 22 payments
  10. Mallinckrodt Enterprises LLC $241 8 payments
  11. Other $2,511 169 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,435 621 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,625 1 payment
  3. Education $32 3 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,991 31 payments
  2. FARXIGA $1,170 60 payments
  3. Kerendia $526 37 payments
  4. AIRSUPRA $521 18 payments
  5. Ozempic $418 38 payments
  6. Wegovy $403 34 payments
  7. REXULTI $388 29 payments
  8. QULIPTA $325 26 payments
  9. RYBELSUS $309 26 payments
  10. NURTEC ODT $279 15 payments
  11. Other $7,478 474 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 254 drugs

Part D claims

28,024

Median for Internal Medicine: 777

Drug cost

$1,586,977

Median for Internal Medicine: $73,373

Branded share of claims

20%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 378 $147,666
Januvia Sitagliptin Phosphate Brand 116 $102,265
Farxiga Dapagliflozin Propanediol Brand 126 $99,113
Jardiance Empagliflozin Brand 122 $97,783
Trulicity Dulaglutide Brand 83 $93,268
Nuplazid Pimavanserin Tartrate Brand 35 $84,031
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 94 $77,416
Ozempic Semaglutide Brand 45 $52,958
Mounjaro Tirzepatide Brand 45 $50,666
Xarelto Rivaroxaban Brand 136 $44,127

The 10 drugs with the highest cost, of 254 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$118,597

Of which drugs: $13,833

Medicare patients

380

Average age 74

Services billed

4,044

207 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Depression 40%
Diabetes 35%
Chronic kidney disease 34%
Ischemic heart disease 32%
COPD 32%
Heart failure 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 30 30 $8,762
Vaccine for influenza for injection into muscle 90662 Office 46 46 $3,696

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $154
  • Lundbeck LLC $35
$189 17 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $173
$173 126 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $143
$143 — —
Wegovy
  • Novo Nordisk Inc $124
$124 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $77
$77 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

625 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record